Saturday, 17 March 2012

Gaviscon Peppermint Flavour Tablets





1. Name Of The Medicinal Product



Gaviscon Peppermint Flavour Tablets.


2. Qualitative And Quantitative Composition



Each tablet contains sodium alginate 250 mg, sodium hydrogen carbonate 133.5 mg and calcium carbonate 80 mg.



Excipients: Aspartame (E951) 3.75 mg per tablet.



For excipients, see Section 6.1.



3. Pharmaceutical Form



Chewable tablet.



An off-white to cream, slightly mottled tablet.



4. Clinical Particulars



4.1 Therapeutic Indications



Treatment of symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn and indigestion (related to reflux), for example, following meals or during pregnancy or in patients with symptoms related to reflux oesophagitis.



4.2 Posology And Method Of Administration



For oral use, after being thoroughly chewed.



Adults and children 12 years and over: Two to four tablets after meals and at bedtime.



Elderly: No dose modifications necessary for this age group.



4.3 Contraindications



This medicinal product is contraindicated in patients with known or suspected hypersensitivity to the active substances or to any of the excipients.



4.4 Special Warnings And Precautions For Use



The sodium content of a four-tablet dose is 246 mg (10.6 mmol). This should be taken into account when a highly restricted salt diet is recommended, e.g. in some cases of congestive cardiac failure and renal impairment.



Each four-tablet dose contains 320 mg (3.2 mmol) of calcium carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi.



Due to its aspartame content this medicinal product should not be given to patients with phenylketonuria.



There is a possibility of reduced efficacy in patients with very low levels of gastric acid.



If symptoms do not improve after seven days, the clinical situation should be reviewed.



Treatment of children younger than 12 years of age is not generally recommended, except on medical advice.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Due to the presence of calcium carbonate which acts as an antacid, a time-interval of 2 hours should be considered between Gaviscon intake and the administration of other medicinal products, especially H2-antihistaminics, tetracyclines, digoxine, fluoroquinolone, iron salt, ketoconazole, neuroleptics, thyroxine, penicilamine, beta-blockers (atenolol, metoprolol, propanolol), glucocorticoid, chloroquine and diphosphonates.



4.6 Pregnancy And Lactation



Open controlled studies in 281 pregnant women did not demonstrate any significant adverse effects of Gaviscon on the course of pregnancy or on the health of the foetus/new-born child. Based on this and previous experience the medicinal product may be used during pregnancy and lactation. Nevertheless, taking into account the presence of calcium carbonate (see Section 5.3) it is recommended to limit the treatment duration as much as possible.



4.7 Effects On Ability To Drive And Use Machines



Not relevant.



4.8 Undesirable Effects



Very rarely (=1/10,000) patients may develop allergic manifestations such as urticaria or bronchospasm, anaphylactic and anaphylactoid reactions.



4.9 Overdose



In the event of overdose symptomatic treatment should be given. The patient may notice abdominal distension.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) ATC code: A02BX.



On ingestion the medicinal product reacts rapidly with gastric acid to form a raft of alginic acid gel having a near neutral pH and which floats on the stomach contents effectively impeding gastro-oesophageal reflux. In severe cases the raft itself may be refluxed into the oesophagus, in preference to the stomach contents, and exert a demulcent effect.



5.2 Pharmacokinetic Properties



The mechanism of action of the medicinal product is physical and does not depend on absorption into the systemic circulation.



5.3 Preclinical Safety Data



There is limited evidence in some reports in animals of delay in calcification of foetal skeleton/bone abnormalities relating to calcium carbonate.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Peppermint flavour



Macrogol 20,000



Mannitol (E421)



Copovidone



Aspartame (E951)



Acesulfame potassium (E950)



Magnesium stearate



6.2 Incompatibilities



Not applicable.



6.3 Shelf Life



2 years.



6.4 Special Precautions For Storage



Do not store above 30°C.



6.5 Nature And Contents Of Container



Unprinted, glass-clear, thermoformable laminate of uPVC/PE/PVdC with aluminium foil lidding blisters packed into cartons.



Blister pack containing 4, 6 or 8 individually sealed tablets.



Larger packs (16, 24, 32, 48 and 64) will be made up of multiples of the above units and packed into cartons.



Pack sizes 4, 6, 8, 16, 24, 32, 48 or 64 tablets



Polypropylene container containing 8, 12, 16, 18, 20, 22 or 24 tablets.



Multiple packs (2 x 16, 2 x 18, 2 x 20, 2 x 22 or 2 x 24) will be packed into cartons.



Pack sizes 8, 12, 16, 18, 20, 22, 24, 2 x 16, 2 x 18, 2 x 20, 2 x 22 or 2 x 24 tablets.



Not all pack sizes may be marketed.



6.6 Special Precautions For Disposal And Other Handling



No special requirements.



7. Marketing Authorisation Holder



Reckitt Benckiser Healthcare (UK) Limited,



Dansom Lane,



Hull,



HU8 7DS,



United Kingdom.



8. Marketing Authorisation Number(S)



PL 00063/0627



9. Date Of First Authorisation/Renewal Of The Authorisation



10/08/2010



10. Date Of Revision Of The Text



10/08/2010




Monday, 12 March 2012

Felodipine



Class: Dihydropyridines
VA Class: CV200
Chemical Name: 4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5 -pyridinedicarboxylic acid ethyl methyl ester
Molecular Formula: C18H19Cl2NO4
CAS Number: 72509-76-3
Brands: Lexxel, Plendil

Introduction

Calcium-channel blocking agent; a 1,4-dihydropyridine derivative.1 2


Uses for Felodipine


Hypertension


Management of hypertension (alone or in combination with other classes of antihypertensive agents).1 2 3 46 51


One of several preferred initial therapies in hypertensive patients with a high risk of developing coronary artery disease and/or diabetes mellitus.77


Can be used as monotherapy for initial management of uncomplicated hypertension; however, thiazide diuretics are preferred by JNC 7.77


Hypertensive Crises


Extended-release felodipine tablets are not suitable for acute treatment of hypertensive urgencies† nor in hypertensive emergencies†7 9 46 51 but may be useful when severe BP elevations continue after initial management of the hypertensive crisis with an appropriate agent.46


Felodipine Dosage and Administration


General


Hypertension



  • Fixed-combination felodipine/enalapril tablets should not be used for initial treatment of hypertension.51 68



Administration


Oral Administration


Administer felodipine alone or in fixed combination with enalapril orally once daily without food or with a light meal.1 51 Avoid concomitant administration with grapefruit juice.1 (See Specific Drugs and Foods under Interactions.)


Swallow extended-release tablets intact; do not chew or crush.1 51


Dosage


Pediatric Patients


Hypertension†

Felodipine Monotherapy

Oral

Initially, 2.5 mg of felodipine once daily.80 Increase dosage as necessary up to a maximum dosage of 10 mg once daily.80


Adults


Hypertension

Felodipine Monotherapy

Oral

Initially, 2.5–5 mg of felodipine once daily.1 9 46 Adjust dosage at approximately monthly intervals (more aggressively in high-risk patients) to achieve BP control.46


Usual felodipine dosage: 2.5–10 mg daily.1 Some experts (JNC 7) state that dosage can be increased to 20 mg daily if necessary and tolerated.46


Felodipine/Enalapril Combination Therapy

Oral

If BP is not adequately controlled by monotherapy with felodipine (or another dihydropyridine-derivative calcium-channel blocking agent) or enalapril (or another ACE inhibitor), can switch to fixed-combination tablets (felodipine 5 mg and enalapril 5 mg; then felodipine 10 mg and enalapril 10 mg).51 If BP control is still inadequate, consider addition of thiazide diuretic.51


Prescribing Limits


Pediatric Patients


Hypertension†

Oral

Maximum 10 mg of felodipine daily.80


Adults


Hypertension

Oral

Maximum 20 mg of felodipine daily.46


Special Populations


The following information addresses dosage of felodipine in special populations.51 Dosages of drugs administered in fixed combination with felodipine also may require adjustment in certain patient populations; the need for such dosage adjustments must be considered in the context of cautions, precautions, and contraindications specific to that population and drug.51


Hepatic Impairment


Usual initial felodipine dosage: 2.5 mg daily.1 51 68 Closely monitor BP response with each dosage adjustment.1


Felodipine/Enalapril Combination Therapy

May use the fixed combination if the optimum maintenance dosage of felodipine and enalapril administered separately corresponds to the amount of the drugs in the fixed combination.51 Amount of felodipine in the fixed combination exceeds the recommended initial dosage for patients with hepatic impairment.51


Renal Impairment


Adjustment of felodipine dosage generally not required.1


Felodipine/Enalapril Combination Therapy

May use the fixed combination if the optimum maintenance dosage of felodipine and enalapril administered separately corresponds to the amount of the drugs in the fixed combination.51 Amount of enalapril in the fixed combination exceeds the recommended initial dosage for patients with severe renal impairment.51


Geriatric Patients


Usual initial felodipine dosage: 2.5 mg daily.1 51 68 Closely monitor BP response with each dosage adjustment.1


Risk of peripheral edema increased substantially with felodipine dosages >10 mg daily.1


Felodipine/Enalapril Combination Therapy

May use the fixed combination if the optimum maintenance dosage of felodipine and enalapril administered separately corresponds to the amount of the drugs in the fixed combination.51 Amount of felodipine in the fixed combination exceeds the recommended initial dosage for geriatric patients.51


Cautions for Felodipine


Contraindications



  • Known hypersensitivity to felodipine or any ingredient in the formulation.1 51



Warnings/Precautions


General Precautions


Angina

Possible hypotension and/or syncope resulting in reflex tachycardia and precipitation of angina pectoris in susceptible patients.1 51


Heart Failure

Safety not established in patients with heart failure; use with caution in patients with heart failure or compromised ventricular function, particularly when used in combination with a β-adrenergic blocker.1


Peripheral Edema

Mild peripheral edema possible within 2–3 weeks of initiating therapy, particularly in older patients (e.g., >60 years of age) receiving higher felodipine dosages (e.g., 20 mg daily).1 51


Use of Fixed Combinations

When felodipine is used in fixed combination with enalapril, consider the cautions, precautions, and contraindications associated with enalapril.51


Specific Populations


Pregnancy

Felodipine: Category C.1 51


Lactation

Not known whether felodipine is distributed into milk; discontinue nursing or the drug.1 51


Pediatric Use

Safety and efficacy remain to be fully established in children;1 51 however, some experts have recommended dosages for hypertension based on current limited clinical experience.80


Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults; select dosage with caution.1 51 (See Geriatric Patients under Dosage and Administration.)


Hepatic Impairment

Felodipine clearance may be decreased.1 (See Special Populations under Pharmacokinetics.) Manufacturer recommends lower initial dosage in patients with hepatic impairment.1 (See Hepatic Impairment under Dosage and Administration.)


Common Adverse Effects


Peripheral edema, headache, flushing.1


Interactions for Felodipine


Metabolized by CYP3A4.1 51


Drugs Affecting Hepatic Microsomal Enzymes


CYP3A4 inhibitors: Potential for increased plasma felodipine concentrations, with possible reduction in BP and increase in heart rate; use with caution.1 51


Specific Drugs and Foods







































Drug or Food



Interaction



Comment



Anticonvulsants (e.g., carbamazepine, phenobarbital, phenytoin)



Decreased plasma felodipine concentrations1 51



Consider use of alternative antihypertensive agents1 51



Antifungals, azoles (itraconazole, ketoconazole)



Increased plasma felodipine concentrations; decreased BP and increased heart rate reported with itraconazole1 51



Cimetidine



Increased plasma felodipine concentrations1 51



Digoxin



Pharmacokinetic interaction unlikely1 51



Erythromycin



Increased plasma felodipine concentrations1 51



Grapefruit juice



Increased oral bioavailability of felodipine1 51



Avoid concomitant use1 51



Indomethacin



Pharmacokinetic interaction unlikely1 51



Metoprolol



Increased plasma metoprolol concentrations1 51



Not considered clinically important1 51



Orange juice



Pharmacokinetic interaction unlikely1 51



Spironolactone



Pharmacokinetic interaction unlikely1 51



Tacrolimus



Increased plasma tacrolimus concentrations1 51



Monitor plasma tacrolimus concentrations1 51


Felodipine Pharmacokinetics


Absorption


Bioavailability


Almost completely absorbed following oral administration but undergoes extensive first-pass metabolism.1 51


Systemic bioavailability of felodipine is approximately 20%.1 51


Onset


Antihypertensive effect evident within 2–5 hours,1 with maximum BP reduction after 1–2 weeks.51


Duration


During chronic administration, substantial BP control lasts for 24 hours, with trough reductions in DBP approximately 40–50% of peak reductions.1


Food


High-fat or high-carbohydrate meal increases peak plasma concentrations but does not affect extent of absorption;1 51 when administered as fixed-combination felodipine/enalapril tablets, high-fat or high-carbohydrate meal also decreases trough (24-hour) plasma concentrations.51 A light meal (e.g., orange juice, toast, and cereal) does not alter felodipine pharmacokinetics.1 51


Distribution


Extent


Crosses the blood-brain barrier.51


Crosses the placenta in animals.1 51


Plasma Protein Binding


>99%.1 51


Elimination


Metabolism


Metabolized in the liver by CYP3A4.1 51


None of the 6 metabolites identified to date has substantial vasodilating activity.1 51


Elimination Route


Eliminated as metabolites, mainly in urine and to a lesser extent in feces.1 51


Half-life


Mean terminal half-life is approximately 11–16 hours following administration as an immediate-release formulation.1 51


Special Populations


Hepatic impairment: Clearance is decreased to about 60% of that observed in young healthy individuals.1 51


Geriatric patients: Felodipine clearance is decreased to about 45% of that observed in young healthy individuals.1 51


Stability


Storage


Oral


Tablets

Felodipine: Tightly closed container at <30°C.1 Protect from light.1


Felodipine/enalapril fixed-combination preparation: Tightly closed container at 25°C (may be exposed to 15–30°C).51 Protect from light and moisture.51


ActionsActions



  • Inhibits the transmembrane influx of extracellular calcium ions across the membranes of myocardial cells and vascular smooth muscle cells, without changing serum calcium concentrations.c




  • Hypotensive effect is principally a consequence of a dose-related reduction in peripheral vascular resistance, with a modest reflex increase in heart rate.1




  • Negative inotropic effects observed in vitro but not in intact animals.1




  • Has no substantial effect on cardiac conduction (PR, PQ, and HV intervals).1



Advice to Patients



  • Risk of mild gingival hyperplasia; importance of good dental hygiene.1




  • Importance of taking felodipine exactly as prescribed.1




  • Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.1 51




  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.1 51




  • Importance of informing patients of other important precautionary information.1 51 (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.























Felodipine

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Tablets, extended-release



2.5 mg



Plendil



AstraZeneca



5 mg



Plendil



AstraZeneca



10 mg



Plendil



AstraZeneca













Felodipine Combinations

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Tablets, extended-release core (felodipine only), film-coated



5 mg with Enalapril Maleate 5 mg



Lexxel



AstraZeneca


Comparative Pricing


This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.


Felodipine 10MG 24-hr Tablets (MYLAN): 100/$192.41 or 200/$384.82


Felodipine 2.5MG 24-hr Tablets (MYLAN): 30/$42.99 or 60/$85.98


Felodipine 5MG 24-hr Tablets (MYLAN): 30/$42.99 or 90/$119.98


Plendil 10MG 24-hr Tablets (ASTRAZENECA LP): 30/$89.99 or 90/$259.95


Plendil 2.5MG 24-hr Tablets (ASTRAZENECA LP): 30/$51.99 or 90/$137.97



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions March 2009. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.


† Use is not currently included in the labeling approved by the US Food and Drug Administration.




References



1. AstraZeneca LP. Plendil (felodipine) extended-release tablets prescribing information. Wayne, PA; 2003 Nov.



2. Saltiel E, Ellrodt AG, Monk JP et al. Felodipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs. 1988; 36:387-428. [IDIS 247636] [PubMed 3069435]



3. Yedinak KC, Lopez LM. Felodipine: a new dihydropyridine calcium-channel antagonist. DICP. 1991; 25:1193-206. [IDIS 287689] [PubMed 1763537]



4. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1984; 144:1045-57. [IDIS 184763] [PubMed 6143542]



5. Anon. Drugs for hypertension. Med Lett Drugs Ther. 1984; 26:107-12. [PubMed 6150424]



6. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1988 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1988; 148:1023-38. [IDIS 242588] [PubMed 3365073]



7. Reviewers’ comments (personal observations).



8. Bailey DG, Spence JD, Munoz C et al. Interaction of citrus juices with felodipine and nifedipine. Lancet. 1991; 337:268-9. [IDIS 277404] [PubMed 1671113]



9. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993; 153:154-83. [IDIS 309043] [PubMed 8422206]



10. Sandoz Pharmaceuticals Corp. DynaCirc (isradipine) capsules prescribing information. East Hanover, NJ; 1992 Jun.



11. Lopez LM, Santiago TM. Isradipine—another calcium-channel blocker for the treatment of hypertension and angina. Ann Pharmacother. 1992; 26:789-99. [IDIS 298260] [PubMed 1535246]



12. Fitton A, Benfield P. Isradipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs. 1990; 40:31-74. [PubMed 2143980]



13. Walton T, Symes LR. Felodipine and isradipine: new calcium-channel blocking agents for the treatment of hypertension. Clin Pharm. 1993; 12:261-75. [IDIS 311530] [PubMed 8458178]



14. Prisant LM, Carr AA, Nelson EB et al. Isradipine vs propranolol in hydrochlorothiazide-treated hypertensives: a multicenter evaluation. Arch Intern Med. 1989; 149:2453-7. [IDIS 260612] [PubMed 2530945]



15. Anon. Isradipine for hypertension. Med Lett Drugs Ther. 1991; 33:51-4. [PubMed 1827655]



16. Alderman MH. Which antihypertensive drugs first—and why! JAMA. 1992; 267:2786-7. Editorial.



17. Weber MA, Laragh JH. Hypertension: steps forward and steps backward: the Joint National Committee fifth report. Arch Intern Med. 1993; 153:149-52. [PubMed 8422205]



18. Glasser SP, Clark PI, Lipicky RJ et al. Exposing patients with chronic, stable, exertional angina to placebo periods in drug trials. JAMA. 1991; 265:1550-4. [PubMed 1671885]



19. National Heart, Lung, and Blood Institute. NHLBI panel reviews safety of calcium channel blockers. Rockville, MD; 1995 Aug 31. Press release.



20. National Heart, Lung, and Blood Institute. New analysis regarding the safety of calcium-channel blockers: a statement for health professionals from the National Heart, Lung, and Blood Institute. Rockville, MD; 1995 Sep 1.



21. Anon. NHLBI panel stands by JNC V in response to Circulation CCB article; AIM report supports use of beta blockers for prevention of sudden cardiac death. F-D-C Rep. 1995; 57(Sep 4):3-4.



22. American Heart Association. Public advisory statement on calcium channel blocker drugs. Dallas, TX; 1995 Aug 28.



23. Psaty BM, Heckbert SR, Koepsell TD et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995; 274:620-5. [IDIS 352203] [PubMed 7637142]



24. Psaty BM, Heckbert SR, Koepsell TD et al. The risk of incident myocardial infarction associated with anti-hypertensive drug therapies. Circulation. 1995; 91:925.



25. Buring JE, Glynn RJ, Hennekens CH. Calcium channel blockers and myocardial infarction: a hypothesis formulated but not yet tested. JAMA. 1995; 274:654-5. [IDIS 352205] [PubMed 7637148]



26. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995; 92:1326-31. [IDIS 353358] [PubMed 7648682]



27. Opie LH, Messerli FH. Nifedipine and mortality: grave defects in the dossier. Circulation. 1995; 92:1068-73. [IDIS 353353] [PubMed 7648646]



28. Kloner RA. Nifedipine in ischemic heart disease. Circulation. 1995; 92:1074-8. [IDIS 353354] [PubMed 7648647]



29. Yusuf S. Calcium antagonists in coronary artery disease and hypertension: time for reevaluation? Circulation. 1995; 92:1079-82. Editorial.



30. Lenfant C. The calcium channel blocker scare: lessons for the future. Circulation. 1995; 91:2855-6. [PubMed 7796490]



31. Habib GB. Are calcium antagonists harmful in hypertensive patients? Distinguishing hype from reality. Chest. 1995; 108:3-5. [IDIS 351406] [PubMed 7606987]



32. Horton R. Spinning the risks and benefits of calcium antagonists. Lancet. 1995; 346:586-7. [IDIS 353102] [PubMed 7650997]



33. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the Second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol. 1991; 67:1295-7. [IDIS 284079] [PubMed 2035457]



34. Egstrup K, Andersen PE Jr. Transient myocardial ischemia during nifedipine therapy in stable angina pectoris, and its relation to coronary collateral flow and comparison with metoprolol. Am J Cardiol. 1993; 71:177-83. [IDIS 308552] [PubMed 8421980]



35. Wagenknecht LE, Furberg CD, Hammon JW et al. Surgical bleeding: unexpected effect of a calcium antagonist. BMJ. 1995; 310:776-7. [IDIS 345035] [PubMed 7711582]



36. Miles Inc. American Heart Association, Dr. Psaty and Miles Inc. release statements qualifying possible risks of calcium channel blockers. West Haven, CT; 1995 Mar 15. Press release.



37. Dear healthcare professional letter regarding calcium-channel blockers and increased risk of heart attack. Chicago:Searle. 1995 Mar 17.



38. McClellan K. Unexpected results from MIDAS in atherosclerosis. Inpharma Wkly. 1994; Apr 9:4.



39. Anon. Groups act to dispel concerns about calcium-channel blockers. Am J Health-Syst Pharm. 1995; 52:1154, 1158. [PubMed 7656105]



40. Waters D. Proischemic complications of dihydropyridine calcium channel blockers. Circulation. 1991; 84:2598-600. [IDIS 295953] [PubMed 1959210]



41. Messerli FH. Case-control study, meta-analysis, and bouillabaisse: putting the calcium antagonist scare into context. Ann Intern Med. 1995; 123:888-9. [IDIS 356631] [PubMed 7486476]



42. Reviewers’ comments (personal observations).



43. Pratt Pharmaceuticals. Procardia (nifedipine) capsules prescribing information (dated 1993 Feb). In: Physicians’ desk reference. 49th ed. Montvale, NJ: Medical Economics Company Inc; 1995:1906-7.



44. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ. 1989; 299:1187-92. [IDIS 260789] [PubMed 2513047]



45. Bailey DG, Arnold JMO, Spence JD. Grapefruit juice and drugs: how significant is the interaction? Clin Pharmcokinet. 1994; 26:91-8.



46. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Bethesda, MD: National Institutes of Health; 1997 Nov. (NIH publication No. 98-4080.)



47. Kaplan NM. Choice of initial therapy for hypertension. JAMA. 1996; 275:1577-80. [IDIS 365188] [PubMed 8622249]



48. Psaty BM, Smith NL, Siscovich DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA. 1997; 277:739-45. [IDIS 380501] [PubMed 9042847]



49. American College of Cardiology and American Heart Association. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1996; 28:1328-428. [IDIS 376249] [PubMed 8890834]



50. Staessen JA, Fagard R, Thijs L et al. for the Systolic Hypertension-Europe (Syst-Eur) Trial Investigators. Morbidity and mortality in the placebo-controlled European Trial on Isolated Systolic Hypertension in the Elderly. Lancet. 1997; 350:757-64. [IDIS 392056] [PubMed 9297994]



51. AstraZeneca LP. Lexxel (enalapril maleate/felodipine) extended-release tablets prescribing information. Wilmington, DE; 2007 Mar.



52. Gradman AH, Cutler NR, Davis PJ et al. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Am J Cardiol. 1997; 9:431-5.



53. Bailey DG, Arnold JMO, Bend JR et al. Grapefruit juice–felodipine interaction: reproducibitlity and characterization with the extended release drug formulation. Br J Clin Pharmacol. 1995; 40:135-40. [IDIS 352052] [PubMed 8562295]



54. Velussi M, Brocco E, Frigato F et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes. 1996; 45:216-22. [IDIS 362953] [PubMed 8549868]



55. Estacio RO, Jeffers BW, Hiatt WR et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998; 338:645-52. [IDIS 400553] [PubMed 9486993]



56. Pahor M, Psaty BM, Furberg CD. Treatment of hypertensive patients with diabetes. Lancet. 1998; 351:689-90. [IDIS 409001] [PubMed 9504510]



57. Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998; 21:597-603. [IDIS 403787] [PubMed 9571349]



58. Byington RP, Craven TE, Furberg CD et al. Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet. 1997; 350:1075-6. [IDIS 393279] [PubMed 10213554]



59. Alderman M, Madhavan S, Cohen H. Calcium antagonists and cardiovascular events in patients with hypertension and diabetes. Lancet. 1998; 351:216-7. [IDIS 398935] [PubMed 9449897]



60. Josefson D. Infarction risk found with calcium channel blocker. BMJ. 1998; 316:797.



61. Cutler JA. Calcium-channel blockers for hypertension—uncertainty continues. N Engl J Med. 1998; 338:679-81. [IDIS 400554] [PubMed 9486999]



62. Bayer, West Haven, CT: Personal communication.



63. Bakris GL, Copley JB, Vicknair N et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996; 50:1641-50. [PubMed 8914031]



64. Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Phramacokinet. 1997; 33:103-21.



65. Roller L. Drugs and grapefruit juice. Clin Pharmacol Ther. 1998; 63:87. [IDIS 398865] [PubMed 9465845]



66. Spence JD. Drugs and grapefruit juice. Clin Pharmacol Ther. 1998; 63:87-8. [IDIS 398865] [PubMed 9465845]



67. Bailey DG, Arnold MO, Munoz C et al. Grapefruit juice—felodipine interaction: mechanism, predictability, and effect of naringin. Clin Pharmacol Ther. 1993; 53:637-42. [IDIS 317108] [PubMed 8513655]



68. Manufacturer’s comments (Astra Merck, Wayne, PA): Personal communication.



69. Bailey DG, Arnold JMO, Spence JD. Grapefruit juice and drugs: how significant is the interaction? Clin Pharmacokinet. 1994; 26:91-8.



71. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Hypertension. 2000; 35:1021-4. [PubMed 10818056]



72. Frohlich ED. Recognition of systolic hypertension for hypertension. Hypertension. 2000; 35:1019-20. [PubMed 10818055]



73. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36:646-61. [IDIS 452007] [PubMed 10977801]



74. Associated Press (American Diabetes Association). Diabetics urged: drop blood pressure. Chicago, IL; 2000 Aug 29. Press Release from web site.



75. Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002; 288:3039-60. [IDIS 490723] [PubMed 12479770]



76. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-97. [IDIS 490721] [PubMed 12479763]



77. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VII) Express. Bethesda, MD: May 14 2003. From NIH website. (Also published in JAMA. 2003; 289.



78. American Diabetes Association. Position statements: treatment of hypertension in adults with diabetes. Diabetes Care. 2003; 26(Suppl 1):S80-S82.



79. Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension. 2003; 21:1011-53.



80. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. The Fourth Report on The Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Pediatrics. 2004; 114(Suppl 2):555-76. [PubMed 15286277]



81. Wright JT, Dunn JK, Cutler JA et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005; 293:1595-607. [IDIS 531054] [PubMed 15811979]



82. Neaton JD, Kuller LH. Diuretics are color blind. JAMA. 2005; 293:1663-6. [IDIS 531056] [PubMed 15811986]



83. Leenen FHH, Nwachuku CE, Black HR et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium-channel blocker versus angiotensin-converting enzyme inhibitor in the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Hypertension. 2006; 48:374-84. [PubMed 16864749]



84. Messerli FH, Staessen JA. Amlodipine better than lisinopril: how one randomized clinical trial ended fallacies from observational studies? Hypertension. 2006; 48:359-61. Editorial.



c. AHFS drug information 2004. McEvoy GK, ed. Nifedipine. Bethesda, MD: American Society of Health-System Pharmacists; 2004:1807-8.



More Felodipine resources


  • Felodipine Side Effects (in more detail)
  • Felodipine Use in Pregnancy & Breastfeeding
  • Drug Images
  • Felodipine Drug Interactions
  • Felodipine Support Group
  • 3 Reviews for Felodipine - Add your own review/rating


  • Felodipine Prescribing Information (FDA)

  • Felodipine MedFacts Consumer Leaflet (Wolters Kluwer)

  • Felodipine Professional Patient Advice (Wolters Kluwer)

  • felodipine Advanced Consumer (Micromedex) - Includes Dosage Information

  • Plendil Prescribing Information (FDA)

  • Plendil Consumer Overview



Compare Felodipine with other medications


  • Angina Pectoris Prophylaxis
  • High Blood Pressure
  • Raynaud's Syndrome

Sunday, 11 March 2012

Gemcitabine


Pronunciation: jem-SYE-ta-been
Generic Name: Gemcitabine
Brand Name: Gemzar


Gemcitabine is used for:

Treating certain types of cancer, including cancers of the ovary, pancreas, lung, and breast. Gemcitabine may be used alone or with other cancer medicines. It may also be used for other conditions as determined by your doctor.


Gemcitabine is an antimetabolite. It works by preventing certain proteins from being made that are necessary for tumor growth.


Do NOT use Gemcitabine if:


  • you are allergic to any ingredient in Gemcitabine

  • you have a blood disorder, difficulty breathing, or a lung disease, or you are receiving radiation therapy

Contact your doctor or health care provider right away if any of these apply to you.



Before using Gemcitabine:


Some medical conditions may interact with Gemcitabine. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have bone marrow suppression, liver or kidney problems, chickenpox, or shingles

  • if you drink alcohol regularly or have a history of alcohol abuse

Some MEDICINES MAY INTERACT with Gemcitabine. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Anticoagulants (eg, warfarin) because the risk of bleeding may be increased

  • Hydantoins (eg, phenytoin) because its effectiveness may be decreased by Gemcitabine, increasing the risk of seizures

This may not be a complete list of all interactions that may occur. Ask your health care provider if Gemcitabine may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Gemcitabine:


Use Gemcitabine as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Gemcitabine is usually administered as an injection at your doctor's office, hospital, or clinic. If you are using Gemcitabine at home, carefully follow the injection procedures taught to you by your health care provider.

  • Do not use Gemcitabine if it contains particles, is cloudy or discolored, or if the vial is cracked or damaged.

  • If Gemcitabine accidentally spills on your skin, wash it off immediately with soap and water. Clean any areas (tables, counter) where Gemcitabine may have spilled or sprayed.

  • Keep this product, as well as syringes and needles, out of the reach of children and pets. Do not reuse needles, syringes, or other materials. Ask your health care provider how to dispose of these materials after use. Follow all local rules for disposal.

  • If you miss a dose of Gemcitabine, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Gemcitabine.



Important safety information:


  • Gemcitabine may cause drowsiness. These effects may be worse if you take it with alcohol or certain medicines. Use Gemcitabine with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • Gemcitabine may reduce the number of clot-forming cells (platelets) in your blood. Avoid activities that may cause bruising or injury. Tell your doctor if you have unusual bruising or bleeding. Tell your doctor if you have dark, tarry, or bloody stools.

  • Gemcitabine may lower the ability of your body to fight infection. Avoid contact with people who have colds or infections. Tell your doctor if you notice signs of infection like fever, sore throat, rash, or chills.

  • Avoid vaccinations with live virus vaccines (eg, measles, mumps, oral polio) while you are taking Gemcitabine. Vaccinations may be less effective.

  • Lab tests, including liver or kidney function, complete blood cell counts, or platelet counts, may be performed while you use Gemcitabine. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

  • Gemcitabine should not be used in CHILDREN; safety and effectiveness in children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: Gemcitabine has been shown to cause harm to the fetus. If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Gemcitabine while you are pregnant. It is not known if Gemcitabine is found in breast milk. Do not breast-feed while you are taking Gemcitabine.


Possible side effects of Gemcitabine:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Abnormal skin sensations; bleeding; blood in the urine; constipation; diarrhea; drowsiness; flu-like symptoms (fever, weakness, loss of appetite, headache, cough, chills, and muscle aches); hair loss; infection (fever, chills, sore throat); itching; loss of appetite; nausea; reaction at the injection site; sleepiness; small red spots under the skin; swelling of the hands or feet; vomiting.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); abdominal pain; confusion; dark urine; difficulty breathing; difficulty urinating or decreased amount of urine; irregular or absent menstrual periods; irregular heartbeat; joint or muscle pain; numbness in the arms or legs; painful or frequent urination; seeing or hearing strange things; seizures; shortness of breath; sores on the mouth or lips; unusual bruising or bleeding; unusual tiredness; yellowing of the skin or eyes.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Gemcitabine side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include decreased ability to fight off infections; severe rash; tingling or numbness in the arms or legs.


Proper storage of Gemcitabine:

Store dry powder of Gemcitabine at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. After mixing, store the solution at room temperature for up to 24 hours. Do not store in the bathroom. Keep Gemcitabine out of the reach of children and away from pets.


General information:


  • If you have any questions about Gemcitabine, please talk with your doctor, pharmacist, or other health care provider.

  • Gemcitabine is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Gemcitabine. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Gemcitabine resources


  • Gemcitabine Side Effects (in more detail)
  • Gemcitabine Use in Pregnancy & Breastfeeding
  • Gemcitabine Drug Interactions
  • Gemcitabine Support Group
  • 0 Reviews for Gemcitabine - Add your own review/rating


  • Gemcitabine Prescribing Information (FDA)

  • gemcitabine Intravenous Advanced Consumer (Micromedex) - Includes Dosage Information

  • Gemcitabine Hydrochloride Monograph (AHFS DI)

  • Gemzar Prescribing Information (FDA)

  • Gemzar Consumer Overview



Compare Gemcitabine with other medications


  • Breast Cancer
  • Breast Cancer, Metastatic
  • Non-Small Cell Lung Cancer
  • Ovarian Cancer
  • Pancreatic Cancer

cefepime Injection


SEF-e-peem


Commonly used brand name(s)

In the U.S.


  • Maxipime

Available Dosage Forms:


  • Powder for Solution

Therapeutic Class: Antibiotic


Pharmacologic Class: 4th Generation Cephalosporin


Uses For cefepime


Cefepime injection is used to treat bacterial infections in many different parts of the body. It belongs to the class of medicines known as cephalosporin antibiotics. It works by killing bacteria or preventing their growth. However, cefepime will not work for colds, flu, or other virus infections.


cefepime is available only with your doctor's prescription.


Before Using cefepime


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For cefepime, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to cefepime or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of cefepime injection in children. However, safety and efficacy have not been established in children younger than 2 months of age.


Geriatric


Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of cefepime injection in the elderly. However, elderly patients are more likely to have age-related kidney problems, which may require caution and an adjustment in the dose for patients receiving cefepime injection.


Pregnancy








Pregnancy CategoryExplanation
All TrimestersBAnimal studies have revealed no evidence of harm to the fetus, however, there are no adequate studies in pregnant women OR animal studies have shown an adverse effect, but adequate studies in pregnant women have failed to demonstrate a risk to the fetus.

Breast Feeding


Studies in women suggest that this medication poses minimal risk to the infant when used during breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.


Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of cefepime. Make sure you tell your doctor if you have any other medical problems, especially:


  • Brain disease (e.g., encephalopathy, severe confusion) or

  • Colitis (inflammation in gut), history of or

  • Diarrhea, severe, history of or

  • Myoclonus (muscle twitching or jerking) or

  • Seizures—Use with caution. May make these conditions worse.

  • Kidney disease—Use with caution. Effects may be increased because of slower removal of the medicine from the body.

Proper Use of cefepime


A nurse or other trained health professional will give you cefepime. cefepime is given as a shot into one of your muscles or through a needle placed in one of your veins.


Precautions While Using cefepime


If your symptoms do not improve within a few days, or if they become worse, check with your doctor.


Cefepime injection may cause diarrhea, and in some cases it can be severe. Do not take any medicine or give medicine to your child to treat diarrhea without first checking with your doctor. Diarrhea medicines may make the diarrhea worse or make it last longer. If you have any questions about this or if mild diarrhea continues or gets worse, check with your doctor.


Check with your doctor right away if you or your child have any of the following symptoms while receiving cefepime: confusion; loss of consciousness; jerking or twitching of the muscles; seizures; seeing, hearing, or feeling things that are not there; or severe sleepiness.


Before you or your child have any medical tests, tell the medical doctor in charge that you are receiving cefepime. The results of some tests may be affected by cefepime.


cefepime Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor or nurse immediately if any of the following side effects occur:


More common
  • Abdominal or stomach cramps

  • back, leg, or stomach pains

  • bleeding gums

  • chills

  • confusion

  • convulsions

  • dark urine

  • difficulty with breathing

  • fever

  • general body swelling

  • headache

  • irregular heartbeats

  • loss of appetite

  • mood or mental changes

  • muscle cramps in the hands, arms, feet, legs, or face

  • nausea or vomiting

  • nosebleeds

  • numbness and tingling around the mouth, fingertips, or feet

  • pale skin

  • shortness of breath

  • sore throat

  • tremor

  • yellowing of the eyes or skin

Less common
  • Bluish color

  • changes in skin color

  • pain

  • swelling of the foot or leg

  • tenderness

Rare
  • Diarrhea

  • inflammation or swelling

  • watery or bloody diarrhea

Incidence not known
  • Agitation

  • back pain

  • blistering, peeling, or loosening of the skin

  • blood in the urine or stools

  • bloody or cloudy urine

  • bloody, black, or tarry stools

  • blurred vision

  • change in consciousness

  • chest pain

  • clay-colored stools

  • cloudy urine

  • coma

  • cough or hoarseness

  • coughing up blood

  • decrease in urine output or decrease in urine-concentrating ability

  • decreased awareness or responsiveness

  • difficult or painful urination

  • difficulty with swallowing

  • dizziness

  • drowsiness

  • fast heartbeat

  • fever with or without chills

  • general feeling of tiredness or weakness

  • high fever

  • hives

  • increased menstrual flow or vaginal bleeding

  • irritability

  • itching

  • joint or muscle pain

  • loss of appetite

  • loss of consciousness

  • lower back or side pain

  • muscle twitching or jerking

  • nosebleeds

  • painful or difficult urination

  • pale skin

  • paralysis

  • pinpoint red spots on the skin

  • prolonged bleeding from cuts

  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue

  • red irritated eyes

  • red or black, tarry stools

  • red or dark brown urine

  • red skin lesions, often with a purple center

  • rhythmic movement of the muscles

  • seeing, hearing, or feeling things that are not there

  • seizures

  • severe sleepiness

  • shortness of breath

  • skin rash

  • sore throat

  • sores, ulcers, or white spots in the mouth or on the lips

  • stiff neck

  • sudden decrease in the amount of urine

  • swollen or painful glands

  • tightness in the chest

  • unpleasant breath odor

  • unusual bleeding or bruising

  • unusual tiredness or weakness

  • vomiting of blood

  • wheezing

  • yellow eyes or skin

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


Less common
  • Red streaks on the skin

  • swelling, tenderness, or pain at the injection site

Rare
  • Itching of the vagina or genital area

  • pain during sexual intercourse

  • redness of the skin

  • sore mouth or tongue

  • thick, white vaginal discharge with no odor or with a mild odor

  • white patches in the mouth, tongue, or throat

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: cefepime Injection side effects (in more detail)



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More cefepime Injection resources


  • Cefepime Injection Side Effects (in more detail)
  • Cefepime Injection Use in Pregnancy & Breastfeeding
  • Cefepime Injection Drug Interactions
  • Cefepime Injection Support Group
  • 0 Reviews for Cefepime Injection - Add your own review/rating


Compare cefepime Injection with other medications


  • Bacteremia
  • Febrile Neutropenia
  • Intraabdominal Infection
  • Kidney Infections
  • Nosocomial Pneumonia
  • Pneumonia
  • Skin and Structure Infection
  • Skin Infection
  • Urinary Tract Infection

Acetazolamide Capsules




Acetazolamide extended-release capsules

Acetazolamide Capsules Description


Acetazolamide extended-release capsules are an inhibitor of the enzyme carbonic anhydrase.


Acetazolamide is a white to faintly yellowish white crystalline, odorless powder, weakly acidic, very slightly soluble in water and slightly soluble in alcohol. The chemical name for acetazolamide is N-(5-Sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide and has the following chemical structure:



MW 222.24                                  C4H6N4O3S2


Each acetazolamide extended-release capsule intended for oral administration contains 500 mg of acetazolamide. In addition, each capsule contains the following inactive ingredients: ammonio methacrylate copolymer dispersion type A and B, FD&C yellow #6, gelatin, microcrystalline cellulose, sodium lauryl sulfate, talc and titanium dioxide. The capsule is printed with black pharmaceutical ink which contains black iron oxide as a coloring agent.



Acetazolamide Capsules - Clinical Pharmacology


Acetazolamide is a potent carbonic anhydrase inhibitor, effective in the control of fluid secretion (e.g., some types of glaucoma), in the treatment of certain convulsive disorders (e.g., epilepsy) and in the promotion of diuresis in instances of abnormal fluid retention (e.g., cardiac edema).


Acetazolamide is not a mercurial diuretic. Rather, it is a non-bacteriostatic sulfonamide possessing a chemical structure and pharmacological activity distinctly different from the bacteriostatic sulfonamides.


Acetazolamide is an enzyme inhibitor that acts specifically on carbonic anhydrase, the enzyme that catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In the eye, this inhibitory action of acetazolamide decreases the secretion of aqueous humor and results in a drop in intraocular pressure, a reaction considered desirable in cases of glaucoma and even in certain non-glaucomatous conditions. Evidence seems to indicate that acetazolamide has utility as an adjuvant in treatment of certain dysfunctions of the central nervous system (e.g., epilepsy). Inhibition of carbonic anhydrase in this area appears to retard abnormal, paroxysmal, excessive discharge from central nervous system neurons. The diuretic effect of acetazolamide is due to its action in the kidney on the reversible reaction involving hydration of carbon dioxide and dehydration of carbonic acid. The result is renal loss of HCO3 ion, which carries out sodium, water, and potassium. Alkalinization of the urine and promotion of diuresis are thus affected. Alteration in ammonia metabolism occurs due to increased reabsorption of ammonia by the renal tubules as a result of urinary alkalinization.


Acetazolamide extended-release capsules provide prolonged action to inhibit aqueous humor secretion for 18 to 24 hours after each dose, whereas tablets act for only eight to 12 hours. The prolonged continuous effect of acetazolamide permits a reduction in dosage frequency.


Plasma concentrations of acetazolamide peak from three to six hours after administration of acetazolamide extended-release capsules, compared to one to four hours with tablets. Food does not affect bioavailability of acetazolamide extended-release capsules.


Placebo-controlled clinical trials have shown that prophylactic administration of acetazolamide at a dose of 250 mg every eight to 12 hours (or a 500 mg controlled-release capsule once daily) before and during rapid ascent to altitude results in fewer and/or less severe symptoms of acute mountain sickness (AMS) such as headache, nausea, shortness of breath, dizziness, drowsiness, and fatigue. Pulmonary function (e.g., minute ventilation, expired vital capacity, and peak flow) is greater in the acetazolamide treated group, both in subjects with AMS and asymptomatic subjects. The acetazolamide treated climbers also had less difficulty in sleeping.



Indications and Usage for Acetazolamide Capsules


For adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide extended-release capsules are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness despite gradual ascent.



Contraindications


Hypersensitivity to acetazolamide or any excipients in the formulation. Since acetazolamide is a sulfonamide derivative, cross sensitivity between acetazolamide, sulfonamides and other sulfonamide derivatives is possible.


Acetazolamide therapy is contraindicated in situations in which sodium and/or potassium blood serum levels are depressed, in cases of marked kidney and liver disease or dysfunction, in suprarenal gland failure, and in hyperchloremic acidosis. It is contraindicated in patients with cirrhosis because of the risk of development of hepatic encephalopathy.


Long-term administration of acetazolamide is contraindicated in patients with chronic non-congestive angle-closure glaucoma since it may permit organic closure of the angle to occur while the worsening glaucoma is masked by lowered intraocular pressure.



Warnings


Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, anaphylaxis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Sensitizations may recur when a sulfonamide is readministered irrespective of the route of administration. If signs of hypersensitivity or other serious reactions occur, discontinue use of this drug.


Caution is advised for patients receiving concomitant high-dose aspirin and acetazolamide, as anorexia, tachypnea, lethargy, metabolic acidosis, coma, and death have been reported.



Precautions



General:


Increasing the dose does not increase the diuresis and may increase the incidence of drowsiness and/or paresthesia. Increasing the dose often results in a decrease in diuresis. Under certain circumstances, however, very large doses have been given in conjunction with other diuretics in order to secure diuresis in complete refractory failure.



Information for Patients:


Adverse reactions common to all sulfonamide derivatives may occur: anaphylaxis, fever, rash (including erythema multiforme, Steven-Johnson syndrome, toxic epidermal necrolysis), crystalluria, renal calculus, bone marrow depression, thrombocytopenic purpura, hemolytic anemia, leukopenia, pancytopenia, and agranulocytosis. Caution is advised for early detection of such reactions and the drug should be discontinued and appropriate therapy instituted.


In patients with pulmonary obstruction or emphysema where alveolar ventilation may be impaired, acetazolamide which may precipitate or aggravate acidosis should be used with caution. Gradual ascent is desirable to try to avoid acute mountain sickness. If rapid ascent is undertaken and acetazolamide is used, it should be noted that such use does not obviate the need for prompt descent if severe forms of high altitude sickness occur, i.e., high altitude pulmonary edema (HAPE) or high altitude cerebral edema.


Caution is advised for patients receiving concomitant high-dose aspirin and acetazolamide, as anorexia, tachypnea, lethargy, metabolic acidosis, coma, and death have been reported (see WARNINGS).


Both increases and decreases in blood glucose have been described in patients treated with acetazolamide. This should be taken into consideration in patients with impaired glucose tolerance or diabetes mellitus.


Acetazolamide treatment may cause electrolyte imbalances, including hyponatremia and hypokalemia, as well as metabolic acidosis. Therefore, periodic monitoring of serum electrolytes is recommended. Particular caution is recommended in patients with conditions that are associated with, or predispose a patient to, electrolyte and acid/base imbalances, such as patients with impaired renal function (including elderly patients; see PRECAUTIONS, Geriatric Use), patients with diabetes mellitus, and patients with impaired alveolar ventilation.


Some adverse reactions to acetazolamide, such as drowsiness, fatigue, and myopia, may impair the ability to drive and operate machinery.



Laboratory Tests:


To monitor for hematologic reactions common to all sulfonamides, it is recommended that a baseline CBC and platelet count be obtained on patients prior to initiating acetazolamide therapy and at regular intervals during therapy. If significant changes occur, early discontinuance and institution of appropriate therapy are important. Periodic monitoring of serum electrolytes is recommended.



Drug Interactions:


Aspirin:


See WARNINGS


Acetazolamide modifies phenytoin metabolism with increased serum levels of phenytoin. This may increase or enhance the occurrence of osteomalacia in some patients receiving chronic phenytoin therapy. Caution is advised in patients receiving chronic concomitant therapy. By decreasing the gastro-intestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. Caution is advised when beginning, discontinuing, or changing the dose of acetazolamide in patients receiving primidone.


Because of possible additive effects with other carbonic anhydrase inhibitors, concomitant use is not advisable.


Acetazolamide may increase the effects of other folic acid antagonists.


Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.


Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.


Acetazolamide may prevent the urinary antiseptic effect of methenamine.


Acetazolamide increases lithium excretion and the lithium may be decreased.


Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.


Acetazolamide may elevate cyclosporine levels.



Drug/laboratory test interactions:


Sulfonamides may give false negative or decreased values for urinary phenolsulfonphthalein and phenol red elimination values for urinary protein, serum non-protein, and serum uric acid. Acetazolamide may produce an increased level of crystals in the urine.


Acetazolamide interferes with the HPLC method of assay for theophylline. Interference with the theophylline assay by acetazolamide depends on the solvent used in the extraction; acetazolamide may not interfere with other assay methods for theophylline.



Carcinogenesis, Mutagenesis, Impairment of Fertility:


Long-term studies in animals to evaluate the carcinogenic potential of acetazolamide has not been conducted. In a bacterial mutagenicity assay, acetazolamide was not mutagenic when evaluated with and without metabolic activation.


The drug had no effect on fertility when administered in the diet to male and female rats at a daily intake of up to 4 times the recommended human dose of 1000 mg in a 50 kg individual.



Pregnancy:



Teratogenic effects:


Pregnancy Category C:


Acetazolamide, administered orally or parenterally, has been shown to be teratogenic (defects of the limbs) in mice, rats, hamsters, and rabbits. There are no adequate and well-controlled studies in pregnant women. Acetazolamide should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.



Nursing Mothers:


Because of the potential for serious adverse reactions in nursing infants from acetazolamide, a decision should be made whether to discontinue nursing or to discontinue the drug taking into account the importance of the drug to the mother. Acetazolamide should only be used by nursing women if the potential benefit justifies the potential risk to the child.



Pediatric Use:


The safety and effectiveness of acetazolamide extended-release capsules in pediatric patients below the age of 12 years have not been established. Growth retardation has been reported in children receiving long-term therapy, believed secondary to chronic acidosis.



Geriatric Use:


Metabolic acidosis, which can be severe, may occur in the elderly with reduced renal function.


In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy.



Adverse Reactions


Body as a whole:


Headache, malaise, fatigue, fever, pain at injection site, flushing, growth retardation in children, flaccid paralysis, anaphylaxis.


Digestive:


Gastrointestinal disturbances such as nausea, vomiting, diarrhea.


Hematological/Lymphatic:


Blood dyscrasias such as aplastic anemia, agranulocytosis, leukopenia, thrombocytopenic purpura, melena.


Hepato-biliary disorders:


Abnormal liver function, cholestatic jaundice, hepatic insufficiency, fulminant hepatic necrosis


Metabolic/Nutritional:


Metabolic acidosis, electrolyte imbalance, including hypokalemia, hyponatremia, osteomalacia with long-term phenytoin therapy, loss of appetite, taste alteration, hyper/hypoglycemia


Nervous:


Drowsiness, paresthesia (including numbness and tingling of extremities and face), depression, excitement, ataxia, confusion, convulsions dizziness


Skin:


Allergic skin reactions including urticaria, photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis


Special senses:


Hearing disturbances, tinnitus, transient myopia


Urogenital:


Crystalluria, increased risk of nephrolithiasis with long-term therapy, hematuria, glycosuria, renal failure polyuria



Overdosage


No specific antidote is known. Treatment should be symptomatic and supportive.


Electrolyte imbalance, development of an acidotic state, and central nervous system effects might be expected to occur. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored.


Supportive measures are required to restore electrolyte and pH balance. The acidotic state can usually be corrected by the administration of bicarbonate.


Despite its high intraerythrocytic distribution and plasma protein binding properties, acetazolamide may be dialyzable. This may be particularly important in the management of acetazolamide overdosage when complicated by the presence of renal failure.



Acetazolamide Capsules Dosage and Administration



Glaucoma:


The recommended dosage is 1 capsule (500 mg) two times a day. Usually 1 capsule is administered in the morning and 1 capsule in the evening. It may be necessary to adjust the dose, but it has usually been found that dosage in excess of 2 capsules (1 g) does not produce an increased effect. The dosage should be adjusted with careful individual attention both to symptomatology and intraocular tension. In all cases, continuous supervision by a physician is advisable.


In those unusual instances where adequate control is not obtained by the twice-a-day administration of acetazolamide extended-release capsules, the desired control may be established by means of acetazolamide (tablets or parenteral). Use tablets or parenteral in accordance with the more frequent dosage schedules recommended for these dosage forms, such as 250 mg every four hours, or an initial dose of 500 mg followed by 250 mg or 125 mg every four hours, depending on the case in question.



Acute Mountain Sickness:


Dosage is 500 mg to 1000 mg daily, in divided doses using tablets or extended-release capsules as appropriate. In circumstances of rapid ascent, such as in rescue or military operations, the higher dose level of 1000 mg is recommended. It is preferable to initiate dosing 24 to 48 hours before ascent and to continue for 48 hours while at high altitude, or longer as necessary to control symptoms.



How is Acetazolamide Capsules Supplied


Acetazolamide Extended-Release Capsules, 500 mg are white to off-white pellets filled in empty hard gelatin capsules with orange opaque cap imprinted with "EP" in black ink and white opaque body imprinted with "107" in black ink and are supplied as follows:


NDC 68382-261-01 in bottle of 100 capsules


NDC 68382-261-10 in bottle of 1000 capsules          



Storage:


Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].


Dispense in well-closed containers.



Manufactured by:


Emcure Pharmaceuticals USA Inc.


21-B, Cotters Lane


East Brunswick, NJ 08816


Distributed by:


Zydus Pharmaceuticals USA Inc.


Pennington,NJ 08534


Rev.: 01/12


Revision Date: 2012/01/28



PACKAGE LABEL.PRINCIPAL DISPLAY PANEL


NDC 68382-261-01 in bottle of 100 tablets


Acetazolamide Extended-release Capsules, 500 mg


Rx only


100 tablets


ZYDUS










ACETAZOLAMIDE 
acetazolamide  capsule, extended release










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)68382-261
Route of AdministrationORALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
ACETAZOLAMIDE (ACETAZOLAMIDE)ACETAZOLAMIDE500 mg




















Inactive Ingredients
Ingredient NameStrength
AMMONIO METHACRYLATE COPOLYMER TYPE A 
AMMONIO METHACRYLATE COPOLYMER TYPE B 
FD&C YELLOW NO. 6 
GELATIN 
CELLULOSE, MICROCRYSTALLINE 
SODIUM LAURYL SULFATE 
TALC 
TITANIUM DIOXIDE 


















Product Characteristics
ColorORANGE (OPAQUE ORANGE) , WHITE (OPAQUE WHITE)Scoreno score
ShapeCAPSULE (CAPSULE)Size25mm
FlavorImprint CodeEP;107
Contains      














Packaging
#NDCPackage DescriptionMultilevel Packaging
168382-261-01100 CAPSULE In 1 BOTTLENone
268382-261-101000 CAPSULE In 1 BOTTLENone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA04090412/15/2008


Labeler - Zydus Pharmaceuticals (USA) Inc. (156861945)

Registrant - Zydus Pharmaceuticals (USA) Inc. (156861945)









Establishment
NameAddressID/FEIOperations
Emcure Pharmaceuticals USA Inc.189630168Analysis, Manufacture
Revised: 02/2012Zydus Pharmaceuticals (USA) Inc.